2025
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline
Yu E, Rumble R, Agarwal N, Cheng H, Eggener S, Bitting R, Beltran H, Giri V, Spratt D, Mahal B, Lu K, Crispino T, Trabulsi E. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. Journal Of Clinical Oncology 2025, 43: 748-758. PMID: 39787437, DOI: 10.1200/jco-24-02608.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerSomatic genomic testingProstate cancerMetastatic castration-resistant prostate cancerClinical trialsCastration-resistant prostate cancerGenomic testingPoly(ADP-ribose) polymerase inhibitorsSystematic reviewMetastatic biopsiesSurvival benefitASCO guidelinesPrognostic informationClinical statusGermline testingPolymerase inhibitorsPatientsScreening implicationsPubMed databaseCancerMultidisciplinary panelEligibility criteriaGermlineLiterature searchSequencing findings
2023
Correlation of HER2 Protein Level With mRNA Level Quantified by RNAscope in Breast Cancer
Li X, Lee J, Gao Y, Zhang J, Bates K, Rimm D, Zhang H, Smith G, Lawson D, Meisel J, Chang J, Huo L. Correlation of HER2 Protein Level With mRNA Level Quantified by RNAscope in Breast Cancer. Modern Pathology 2023, 37: 100408. PMID: 38135153, DOI: 10.1016/j.modpat.2023.100408.Peer-Reviewed Original ResearchHER2 protein levelsHER2-low breast cancerT-DXdBreast cancerRNA levelsProtein levelsHER2 expressionEarly-stage breast cancerIHC H-scoresTrastuzumab deruxtecanTissue microarray coresClinical trialsMetastatic biopsiesImmunohistochemical assaysH-scoreDrug AdministrationResponse rateUS FoodPatientsIHC assaysCancerRNAscopeRegression analysisCell linesImmunofluorescence scores
2018
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies
Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, Painter C, Freeman S, Persky NS, Marini L, Helvie K, Oliver N, Rozenblatt-Rosen O, Ma CX, Regev A, Winer EP, Lin NU, Wagle N. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies. Nature Genetics 2018, 51: 207-216. PMID: 30531871, DOI: 10.1038/s41588-018-0287-5.Peer-Reviewed Original ResearchConceptsHER2 mutationsEstrogen receptorBreast cancerClinical resistance mechanismsMainstay of treatmentMetastatic breast cancerReceptor-directed therapyCDK6 inhibitor palbociclibPre-existing mutationsMetastatic settingEstrogen independenceInhibitor palbociclibPrimary tumorMetastatic biopsiesInhibitor neratinibTherapyPatientsER mutationsCancerTamoxifenResistance mechanismsDistinct mechanismsMutationsConfer resistanceBiopsy
2016
A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer.
Wagle N, Helvie K, Lloyd M, Marini L, Waks A, Cohen O, Oh C, Sougnez C, Oliver N, Quartey Q, Rotem A, Shah P, Lindeman N, Krop I, Garraway L, Winer E, Lin N. A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer. Journal Of Clinical Oncology 2016, 34: 11513-11513. DOI: 10.1200/jco.2016.34.15_suppl.11513.Peer-Reviewed Original Research
2012
Abstract 3697: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer - SU2C-001
Barrett M, Lenkiewicz E, Evers L, Holley T, Aziz M, Kiefer J, Maitra A, Hidalgo M, Kumar R, Hlavacek W, Stites E, Posner R, Ramanathan R, Von Hoff D. Abstract 3697: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer - SU2C-001. Cancer Research 2012, 72: 3697-3697. DOI: 10.1158/1538-7445.am2012-3697.Peer-Reviewed Original ResearchComparative genomic hybridizationPhase II studyStudies of therapyMolecular profilingTreating metastatic pancreatic cancerK-rasPanel of xenograftsAneuploid tumour cell populationsMetastatic pancreatic cancerComparative genomic hybridization arrayAmerican Association for Cancer ResearchTherapeutic targetK-ras mutationsTumor cell populationGene expression microarray analysisExpression microarray analysisFocal ampliconsMetastatic lesionsMetastatic biopsiesC-kitGenomic hybridizationPancreatic cancerTumor nucleiHomozygous deletionDrug sensitivity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply